Chronic Hand Eczema (CHE) - Epidemiology Forecast - 2030

‘Chronic Hand Eczema (CHE)– Epidemiology Forecast—2030’ report delivers an in-depth understanding of the CHE, historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Chronic Hand Eczema (CHE) Disease Understanding
Hand eczema (HE) are non-infectious, inflammatory cutaneous lesions and belongs to the most common skin disorder exclusively localized to the hands. It is a highly prevalent, multi-etiological disease with a wide spectrum of severity and chronicity. In a substantial number of patients, HE can develop into a chronic condition, which remains active even after avoidance potentially damaging allergens and/or irritants.
Chronic Hand Eczema (CHE) has been defined as a long-lasting, relapsing course of Hand Eczema that is
• Disease duration of at least 3 months or more than 3 flares within the last 12 months,
• Unresponsive to standard treatment with emollients and topical corticosteroids for more than 3 months,
• The recurrence of symptoms two or more times within a year despite adequate treatment.
• No dominating active severe skin diseases or acute skin infections
CHE as an anatomoclinic syndrome with multifactorial origins that is not restricted to allergic or orthoergic origin. Clinical features include localization of eczema to the hands and fingers, including dryness, erythema, edema, hyperkeratosis, scaling, lichenification, vesiculation/blistering, fissures, pruritus, and pain. It is typically a dynamic condition extending over the years, and its morphology may change with time, both clinically and histologically. Erythema, edema, and vesicles are characteristic of acute eczema, whereas infiltration, hyperkeratosis, and fissures are seen in chronic eczema. It has significant morbidity and lost earnings and has severe negative impacts on the social and psychosocial aspects of patients’ lives.
Chronic Hand Eczema (CHE) Epidemiology
The CHE epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Report report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Key Findings
The total diagnosed prevalent cases of Chronic Hand Eczema (CHE) patients 7MM during the study period, i.e. 2017-2030.
The disease epidemiology covered in the report provides historical as well as forecasted CHE symptoms epidemiology segmented as the Total prevalence of CHE, Gender-Specific cases of CHE, Diagnosed cases of CHE, Age-Specific cases of CHE, Severity Specific Cases of CHE and Subgroup Specific Cases of CHE. The report includes the prevalent scenario of CHE symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.
The prevalence of Chronic Hand Eczema (CHE) in the 7MM is expected to increase during the study period of 2017–2030.
Country Wise- Chronic Hand Eczema (CHE) Epidemiology
The epidemiology segment also provides the Chronic Hand Eczema (CHE) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
According to Report, The total prevalent population of CHE Associated in 7MM countries ranges from 4,229,215 in 2017.
• As per the estimates, United States has the highest prevalent population of CHE.
• Among the EU5 countries, Germany had the highest prevalent population of CHE, followed by France and the UK. On the other hand, Spain had the lowest prevalent population in 2017.
• On the other hand, Japan had 632,395 prevalent cases of Chronic Hand Eczema in 2017.
Scope of the Report
• The Chronic Hand Eczema (CHE) report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• The Chronic Hand Eczema (CHE) Epidemiology Report and Model provide an overview of the risk factors and global trends of Chronic Hand Eczema (CHE) in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
• The report provides insight about the historical and forecasted patient pool of Chronic Hand Eczema (CHE) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) and Japan
• The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
• The report assesses the disease risk and burden and highlights the unmet needs of CHE
• The report provides the segmentation of the Chronic Hand Eczema (CHE) epidemiology by Prevalent Cases of Chronic Hand Eczema (CHE) in 7MM.
• The report provides the segmentation of the Chronic Hand Eczema (CHE) epidemiology by Gender - specific Prevalent Cases of Chronic Hand Eczema (CHE) in 7MM.
• The report provides the segmentation of the Chronic Hand Eczema (CHE) epidemiology by Age-specific Prevalent Cases of Chronic Hand Eczema (CHE) in 7MM.
• The report provides the segmentation of the Chronic Hand Eczema (CHE) epidemiology by Sub group-specific Cases of Chronic Hand Eczema (CHE) in 7MM
• The report provides the segmentation of the Chronic Hand Eczema (CHE) epidemiology by Diagnosed Cases of Chronic Hand Eczema (CHE) in 7MM
• The report provides the segmentation of the Chronic Hand Eczema (CHE) epidemiology by Severity Specific Cases of Chronic Hand Eczema (CHE) in 7MM

Report Highlights
• 11-Year Forecast of Chronic Hand Eczema (CHE) epidemiology
• 7MM Coverage
• Total Prevalent Cases of Chronic Hand Eczema (CHE)
• Prevalent Cases according to segmentation: Age-specific Prevalence of CHE
• Prevalent Cases according to segmentation: Gender-specific Prevalence of CHE
• Prevalent Cases according to segmentation: Diagnosed cases of CHE
• Prevalent Cases according to segmentation: Severity Specific cases of CHE
• Prevalent Cases according to segmentation: Subgroup Specific Cases of CHE

KOL- Views
We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.
Key Questions Answered
• What will be the growth opportunities in the 7MM with respect to the patient population pertaining to CHE?
• What are the key findings pertaining to the Chronic Hand Eczema (CHE) epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017–2030)?
• What would be the total number of patients of Chronic Hand Eczema (CHE) across the 7MM during the forecast period (2017–2030)?
• Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017–2030)?
• At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017–2030)?
• What is the disease risk, burden and unmet needs of the CHE?
• What are the currently available treatments of CHE?

Reasons to buy
The Chronic Hand Eczema (CHE) Epidemiology report will allow the user to -
• Develop business strategies by understanding the trends shaping and driving the global Chronic Hand Eczema (CHE) market
• Quantify patient populations in the global Chronic Hand Eczema (CHE) market to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Chronic Hand Eczema (CHE) therapeutics in each of the markets covered
• Understand the magnitude of Chronic Hand Eczema (CHE) population by its Prevalence cases
• Understand the magnitude of Chronic Hand Eczema (CHE) population by its Gender-specific cases
• Understand the magnitude of Chronic Hand Eczema (CHE) population by its Age-specific cases
• Understand the magnitude of Chronic Hand Eczema (CHE) population by its Diagnosed- specific cases
• Understand the magnitude of Chronic Hand Eczema (CHE) population by its Severity - specific cases
• Understand the magnitude of Chronic Hand Eczema (CHE) population by its subgroup-specific cases
• The Chronic Hand Eczema (CHE) epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists
• The Chronic Hand Eczema (CHE) Epidemiology Model developed by Report is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources
Key Assessments
• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population
Geographies Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2017–2030
As per the National Eczema Association, Hand Eczema/Hand Dermatitis is a very common condition affecting up to 10% of the population. The same number of estimation is found in the Thyssen et al., (2010) and others. Chronic Hand Eczema is estimated to occur in 5–7% of patients with Hand Eczema. As per Diepgen et al., Severe chronic HE has a major adverse impact on economic and social functions, with although abundant treatment options but with limited efficacy.
The chronic hand eczema registry on long-term patient management (CARPE) registry is the worldwide first registry of CHE that has been initiated in Germany which has a great contribution to health care research of chronic hand eczema. The CARPE was initiated in 2009, with the aim to investigate characteristics and treatment modalities in patients affected by chronic hand eczema in Germany. CARPE Registry-2015 found that mean disease duration was almost 8 years and CHE was graded as very severe or severe in approximately 70% of affected patients. Overall, 41% of patients had an atopic background and a type IV sensitization was reported in 48% of patients. Atopic hand eczema and allergic contact dermatitis were, however, reported in 34% and 22%.
Currently, register on patients with chronic hand eczema data from CARPE and a Swiss “sister-registry” showed that a significant proportion of patients may not receive adequate treatment according to guidelines. Future research will need to make use of longitudinal data to study the course of the disease and the effectiveness of different therapies in a comparative manner